s
s
s
Develop highly selective and sensitive PK and ADA assays for daratumumab (Darzalex) using our range of ready-made antibodies.
Table 1. Antibodies Specific to Daratumumab.
Specificity |
Catalog Number |
Clone |
Format |
Affinity* KD, nM |
Assay Recommendation |
Product Details |
---|---|---|---|---|---|---|
Daratumumab Inhibitory Type 1 |
HCA364 |
AbD45015ia |
Human IgG1 |
0.9 |
PK bridging ELISA capture and detection ADA control |
|
HCA365 |
AbD44788ia |
Human IgG1 |
3 |
ADA control |
||
HCA366 |
AbD44786ia |
Human IgG1 |
9 |
ADA control |
* Affinity measured in the monovalent Fab format.
Type 1 anti-daratumumab antibodies inhibit the binding of the monoclonal antibody drug daratumumab to its target, CD38. They are ideal for development of a pharmacokinetic (PK) bridging ELISA to measure free drug. They are available in fully human IgG1 format, in three different affinities, for use as a surrogate positive control or reference standard for an anti-drug antibody (ADA) assay.
Fig. 1. Daratumumab PK bridging ELISA using antibody HCA364.
Schematic image of PK bridging ELISA. Anti-idiotypic capture and detection antibodies, Ig format (blue), monoclonal antibody drug (gold), detection antibody labeled with HRP.
Fig. 2. Daratumumab ADA bridging ELISA using antibody HCA364, HCA365, or HCA366.
Schematic image of ADA bridging assay. Monoclonal antibody drug as capture antibody and detection antibody labeled with HRP (gold), fully human anti-idiotypic antibody, Ig format (blue).
Licensed Use: For in vitro research purposes and for commercial applications for the provision of in vitro testing services to support preclinical and clinical drug development. Any re-sale in any form or any other commercial application needs a written agreement with Bio-Rad.